Education
About Us
Working with TipRanks
Follow Us
Kiora Pharmaceuticals (KPRX)
NASDAQ:KPRX
Total Valuation
Kiora Pharmaceuticals has a market cap or net worth of $9.06M. The enterprise value is -$16.83M.
Market Cap$9.06M
Enterprise Value-$16.83M
Share Statistics
Kiora Pharmaceuticals has 3,000,788 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,000,788
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Kiora Pharmaceuticals’s return on equity (ROE) is 0.14 and return on invested capital (ROIC) is 9.39%.
Return on Equity (ROE)0.14
Return on Assets (ROA)0.10
Return on Invested Capital (ROIC)9.39%
Return on Capital Employed (ROCE)0.15
Revenue Per Employee1.33M
Profits Per Employee299.56K
Employee Count12
Asset Turnover0.44
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kiora Pharmaceuticals is 3.56. Kiora Pharmaceuticals’s PEG ratio is -0.03.
PE Ratio3.56
PS Ratio0.62
PB Ratio0.50
Price to Fair Value0.50
Price to FCF1.49
Price to Operating Cash Flow1.49
PEG Ratio-0.03
Income Statement
In the last 12 months, Kiora Pharmaceuticals had revenue of 16.02M and earned 3.59M in profits. Earnings per share was 1.99.
Revenue16.02M
Gross Profit16.02M
Operating Income4.51M
Pretax Income5.66M
Net Income3.59M
EBITDA5.70M
Earnings Per Share (EPS)1.99
Cash Flow
In the last 12 months, operating cash flow was 8.56M and capital expenditures -6.26K, giving a free cash flow of 8.55M billion.
Operating Cash Flow8.56M
Free Cash Flow8.55M
Free Cash Flow per Share2.85
Dividends & Yields
Kiora Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.74
52-Week Price Change-25.93%
50-Day Moving Average3.11
200-Day Moving Average3.53
Relative Strength Index (RSI)59.35
Average Volume (3m)9.78K
Important Dates
Kiora Pharmaceuticals upcoming earnings date is May 7, 2025, TBA Not Confirmed.
Last Earnings DateMar 25, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend Date―
Financial Position
Kiora Pharmaceuticals as a current ratio of 4.94, with Debt / Equity ratio of 0.22%
Current Ratio4.94
Quick Ratio4.94
Debt to Market Cap<0.01
Net Debt to EBITDA-0.66
Interest Coverage Ratio210.31
Taxes
In the past 12 months, Kiora Pharmaceuticals has paid 2.07M in taxes.
Income Tax2.07M
Effective Tax Rate0.36
Enterprise Valuation
Kiora Pharmaceuticals EV to EBITDA ratio is 1.59, with an EV/FCF ratio of 1.06.
EV to Sales0.56
EV to EBITDA1.59
EV to Free Cash Flow1.06
EV to Operating Cash Flow1.06
Balance Sheet
Kiora Pharmaceuticals has $26.79M in cash and marketable securities with $94.30K in debt, giving a net cash position of -$26.73M billion.
Cash & Marketable Securities$26.79M
Total Debt$94.30K
Net Cash-$26.73M
Net Cash Per Share-$8.91
Tangible Book Value Per Share$4.92
Margins
Gross margin is 0.00%, with operating margin of 28.15%, and net profit margin of 22.44%.
Gross Margin0.00%
Operating Margin28.15%
Pretax Margin35.33%
Net Profit Margin22.44%
EBITDA Margin35.58%
EBIT Margin35.46%
Analyst Forecast
The average price target for Kiora Pharmaceuticals is $10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$10.00
Price Target Upside212.50% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―